Pegfilgrastim

Leukocyte Growth Factor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Pegfilgrastim is a drug in the Leukocyte Growth Factor class catalogued in DrugCentral. It was first approved by the FDA in 2002. DrugCentral lists 1 molecular target, including CSF3R. Recorded indications include Allogeneic peripheral blood stem cell transplant and Chemotherapy-induced neutropenia.

• Drug class: Leukocyte Growth Factor.
• Molecular targets: CSF3R (1 listed in DrugCentral).
• Indications: Allogeneic peripheral blood stem cell transplant and Chemotherapy-induced neutropenia.
• ATC code: L03AA13 (Colony stimulating factors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Allogeneic peripheral blood stem cell transplant
• Chemotherapy-induced neutropenia

Mechanism & targets

• Established pharmacologic class: Leukocyte Growth Factor

Molecular targets (1)

Target	Gene	Action	Activity
Granulocyte colony-stimulating factor receptor	CSF3R	activator	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2014-09-26	PMDA	—	Kyowa Hakko Kirin Co., Ltd.
2002-08-22	EMA	—	Amgen Europe B.V.
2002-01-31	FDA	—	AMGEN

ATC classification

ATC code	Therapeutic hierarchy
L03AA13	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Device adhesion issue	63766.5
Unintentional medical device removal	48313.4
Wrong technique in product usage process	28194.9
Device use error	27756.5
Device malfunction	26906.7
Device issue	15157.6
Accidental exposure to product	14790.2
Device occlusion	12634.2
Application site haemorrhage	6535.0
Drug dose omission by device	6419.6
Occupational exposure to product	6360.0
Intercepted product preparation error	5825.4

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 208265-92-3
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pegfilgrastim used for?

DrugCentral lists the following indications for Pegfilgrastim: Allogeneic peripheral blood stem cell transplant and Chemotherapy-induced neutropenia.

How does Pegfilgrastim work?

Its molecular targets in DrugCentral include CSF3R (activator).

When was Pegfilgrastim first approved?

Pegfilgrastim was first approved by the FDA in 2002.

What drug class does Pegfilgrastim belong to?

Pegfilgrastim is in the Leukocyte Growth Factor class.

Sources

• DrugCentral drug card 4986 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201568 — compound record and bioactivity
• DrugBank DB00019 — drug record
• FDA UNII 3A58010674 — substance identity
• DailyMed: FDA labels for Pegfilgrastim — current prescribing information (label search)
• UniProt Q99062 (CSF3R) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.